CD155 (PVR)
CD155 is the molecule on tumour cells that TIGIT and CD96 read; normal tissue barely shows it, many tumours show a lot. Every TIGIT antibody works by breaking the CD155 handshake.
Overview
PVR (chromosome 19q13.31) encodes CD155, which mediates NK-cell adhesion and triggers NK effector functions through two NK-cell receptors, CD96 and CD226, at the immunological synapse (UniProt P15151). It is barely or weakly expressed in various normal human tissues but frequently over-expressed in malignant tumours, promotes invasion and migration, is associated with poor prognosis, and as the ligand of the co-stimulatory receptor CD226 and the co-inhibitory receptors TIGIT and CD96 it plays a dual role in onco-immunity (Kučan Brlić et al. 2017, Cell Mol Immunol).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CD155 is the molecule on tumour cells that TIGIT and CD96 read; normal tissue barely shows it, many tumours show a lot. Every TIGIT antibody works by breaking the CD155 handshake.
- 1 · What it is
CD155 is the molecule on tumour cells that TIGIT and CD96 read; normal tissue barely shows it, many tumours show a lot. Every TIGIT antibody works by breaking the CD155 handshake.
- 2 · What goes wrong in cancer
A nectin-like adhesion molecule and the poliovirus receptor; the shared ligand of the DNAM-1/TIGIT/CD96 axis.
- 3 · How drugs use it
No product in this corpus aims at CD155 (PVR) yet. Checkpoint drugs are antibodies that cover one side of an immune ‘stand down’ handshake so T cells stay active.
External identifiers
Sources: HGNC HGNC:9705 (approved symbol, name, aliases and cross-references); UniProt P15151 (protein name, function and tissue specificity)
Biology
A nectin-like adhesion molecule and the poliovirus receptor; the shared ligand of the DNAM-1/TIGIT/CD96 axis.
- Weak in normal tissue, frequently over-expressed in malignant tumours (Kučan Brlić et al. 2017)
Notes
top- Prevalence not recorded: HGNC and UniProt carry no positivity rates.
Latest papers
topQuery for this target: (TITLE:"CD155" OR ABSTRACT:"CD155" OR TITLE:"PVR" OR ABSTRACT:"PVR" OR TITLE:"poliovirus receptor" OR ABSTRACT:"poliovirus receptor" OR TITLE:"Necl-5" OR ABSTRACT:"Necl-5" OR TITLE:"NECL5" OR ABSTRACT:"NECL5" OR TITLE:"PVS" OR ABSTRACT:"PVS") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CD155 (PVR), not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPVRIG (CD112R)
Shares CD112 (nectin-2), TIGIT blockade, TIGIT, The cancer-immunity cycle and the tag checkpoint-map.
- TargetTDO2
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetCD39 (ENTPD1)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetLILRB1 (ILT2)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetHHLA2 (B7-H7)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetGITR (TNFRSF18)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetCD27
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.
- TargetAdenosine A2A receptor (ADORA2A)
Shares The cancer-immunity cycle, Checkpoint (two meanings) and the tag checkpoint-map.